GSK Reportedly To Lay Off 1,000 In China
This article was originally published in Scrip
After a stormy year in China, GlaxoSmithKline has gone through major changes including the global transfer of its oncology assets to Novartis. But the underlying broader reasons for the company's newly reported layoffs in China could be more deep-rooted and far-reaching.
You may also be interested in...
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
The move may signal China is accelerating the vaccine to hit the general market soon, but a false impression of the vaccine’s safety may be potentially misleading, says one regulatory expert.